Real-world data for precision cancer medicine
Major Nordic national medicines authority
Ongoing validation of new cancer medicines in real-world patient populations, against fragmented national health registries.
Privacy-preserving pipeline over LPR3-class inpatient data, pharmacy dispensing, and civil-registry linkage, with reusable protocol templates that compress follow-up cycles from nine months to three.